Plasma tau and neurodegenerative markers as predictors of rate of AD progression

血浆 tau 蛋白和神经退行性标记物作为 AD 进展率的预测因子

• 批准号: 10633231
• 负责人: JASMEER P CHHATWAL
• 金额: $ 84.82万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-30 至 2026-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10633231
• 关键词: Affect; Alzheimer' s Disease; Alzheimer' s disease diagnosis; Alzheimer' s disease pathology; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Amyloid; Biological Markers; Blood; Caregivers; Clinic; Clinical; Clinical Research; Cognition; Cognitive; Cross-Sectional Studies; Data; Dementia; Diagnosis; Disease Progression; Family; Family health status; Funding; Healthcare Systems; Hippocampus; Image; Immunoassay; Impaired cognition; Impairment; Light; Magnetic Resonance Imaging; Measures; Medical; Memory Loss; Modeling; N-terminal; Nerve Degeneration; Neurology; Participant; Pathologic; Pathology; Patients; Performance; Persons; Plasma; Population; Positron-Emission Tomography; Probability; Public Health; Research; Research Personnel; Risk; Sampling; Signal Transduction; Spinal Puncture; Syndrome; Time; Uncertainty; amyloid precursor protein processing; blood-based biomarker; clinical care; clinical diagnosis; clinical diagnostics; clinical predictors; cognitive performance; cost; design; diagnostic tool; flexibility; functional decline; imaging biomarker; improved; in vivo; neurofilament; neuroimaging; novel; predictive marker; prognostic model; prospective; relative cost; research study; risk stratification; secretase; tau Proteins; tau aggregation; tau-1; tool; β-amyloid burden

Project Abstract: Alzheimer's disease and related dementias (ADRD) affect tens of millions of people around the world and represent a staggering challenge for patients, families, and healthcare systems. For some who present with mild levels of cognitive impairment, there is rapid worsening of cognition and function, whereas for others, the rate of progression can be absent or much slower. Understanding this variability in rate of progression is critically important to patients, families, and clinical researchers alike, and is not well-predicted by common, clinically available biomarker tools. Blood-based markers of AD pathology and neurodegeneration have potential for widespread use in clinical research and even clinical care, due to their non-invasiveness, cost relative to neuroimaging, and lack of medical contraindications to limit their use. Here we examine a set of newly developed, blood-based AD biomarkers (including neurofilament light chain, phospho-tau species, tau, and Ab fragments) that may fill this gap. Leveraging prospectively acquired samples from a large clinic population and from local clinical research studies, we will determine how these plasma measures relate to variable rates of "real-world" cognitive and functional decline, as well as to imaging-based measures of neurodegeneration and AD pathologic progression.

项目简介:

项目成果

Uncovering elevated tau TPP motif phosphorylation in the brain of Alzheimer's disease patients.

揭示阿尔茨海默病患者大脑中 tau TPP 基序磷酸化水平升高。

• DOI: 10.1002/alz.13557
• 发表时间: 2024
• 期刊: Alzheimer's & dementia : the journal of the Alzheimer's Association
• 作者: Bellier,Jean-Pierre;Cai,Yuqi;Alam,SarahM;Wiederhold,Thorsten;Aiello,Arica;Vogelgsang,JonathanS;Berretta,Sabina;Chhatwal,JasmeerP;Selkoe,DennisJ;Liu,Lei
• 通讯作者: Liu,Lei